ChemSpider 26387125
Chemical and physical data
Formula C15H15N3O2S2
Molar mass 333.42 g·mol−1
3D model (Jmol) Interactive image

AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia.[1][2][3] In early 2011, it successfully completed phase IIa clinical trials,[1][4] with benefits on positive symptoms and some procognitive effects observed,[5] and in mid 2013, phase IIb clinical trials for schizophrenia began.[6] Avineuro Pharmaceuticals has also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.[6][7]

See also


  1. 1 2 Sylvain Celanire; Sonia Poli (13 October 2014). Small Molecule Therapeutics for Schizophrenia. Springer. pp. 31, 37. ISBN 978-3-319-11502-3.
  2. Pharmacology of 5-HT6 receptors. Academic Press. 7 December 2010. pp. 164–. ISBN 978-0-12-384977-9.
  3. "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
  4. http://www.avineuro.com/avineuro-pharmaceuticals-inc-reports-positive-phase-2a-clinical-proof-of-concept-trial-results-on-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/
  5. Morozova, Margarita A.; Lepilkina, Taisiya A.; Rupchev, Georgy E.; Beniashvily, Allan G.; Burminskiy, Denis S.; Potanin, Sergey S.; Bondarenko, Evgeny V.; Kazey, Vasily I.; Lavrovsky, Yan; Ivachtchenko, Alexandre V. (2013). "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study". CNS Spectrums. 19 (04): 316–323. doi:10.1017/S1092852913000394. ISSN 1092-8529.
  6. 1 2 http://www.avineuro.com/avineuro-pharmaceuticals-inc-announces-beginning-of-phase-2b-clinical-studies-of-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/
  7. Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA (2016): "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer’s Disease", Molecular Pharmaceutics, 13 (3), 945–963. PMID 26886442

External links

This article is issued from Wikipedia - version of the 9/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.